Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Spatial Treg niches and the therapeutic reprogramming of tumour tolerance in cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Regulatory T cells in skin facilitate epithelial stem cell differentiation
10.1016/j.cell.2017.05.002 · 2017 · External reference
Foxp3 reprograms T cell metabolism to function in low-glucose, high-lactate environments
10.1016/j.cmet.2016.12.018 · 2017 · External reference
Fc-Optimized Anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors
10.1016/j.immuni.2017.03.013 · 2017 · External reference
Genetic and epigenetic variation in the lineage specification of regulatory T cells
10.7554/elife.07571 · 2015 · External reference
Single-cell map of diverse immune phenotypes in the breast tumor microenvironment
10.1016/j.cell.2018.05.060 · 2018 · External reference
Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade
10.1136/jitc-2020-002231 · 2021 · External reference
Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer
10.1016/j.lungcan.2018.01.022 · 2018 · External reference
Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse
10.1200/jco.2006.05.9584 · 2006 · External reference
Mitochondrial drivers of stem cell aging and inflammaging
10.1038/s41514-026-00422-5 · External reference
The hallmarks of neuro-immune reprogramming in cancer
10.3389/fimmu.2026.1806570 · External reference
Neurodegeneration rewires the tumor microenvironment via the neuro-immune-cancer axis
10.1016/j.isci.2025.113550 · 2025 · External reference
Programming the tumor microenvironment through microbiome-driven mechanisms
10.3389/fcimb.2026.1857151 · External reference
Next‐generation immune checkpoints and tumor microenvironment modulation in cancer immunotherapy
10.1155/jimr/7864229 · External reference
Gut microbiome-driven colorectal cancer via immune, metabolic, neural, and endocrine axes reprogramming
10.1038/s41522-025-00883-8 · External reference
Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy
10.1172/jci89455 · 2017 · External reference
Sirtuin-1 targeting promotes Foxp3+ T-regulatory cell function and prolongs allograft survival
10.1128/mcb.01206-10 · 2011 · External reference
The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3
10.1038/83713 · 2001 · External reference
Regulatory T cells in cancer
10.1182/blood-2006-02-002774 · 2006 · External reference
Understanding the tumor immune microenvironment (TIME) for effective therapy
10.1038/s41591-018-0014-x · 2018 · External reference
Unleashing Type-2 dendritic cells to drive protective antitumor CD4+ T cell immunity
10.1016/j.cell.2019.02.005 · 2019 · External reference
Abstract CT232: preliminary results of a phase 1, first-in-human, dose-escalation study of the anti-CCR8 antibody denikitug in participants with advanced solid tumors
10.1158/1538-7445.am2026-ct232 · 2026 · External reference
Multiplexed epitope-based tissue imaging for discovery and healthcare applications
10.1016/j.cels.2016.03.008 · 2016 · External reference
Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression
10.1182/blood-2006-12-064527 · 2007 · External reference
Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity
10.1016/j.ccell.2014.09.007 · 2014 · External reference
Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse
10.1038/83784 · 2001 · External reference
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
10.1084/jem.20130573 · 2013 · External reference
Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial
10.1038/s41591-024-03083-7 · 2024 · External reference
A special population of regulatory T cells potentiates muscle repair
10.1016/j.cell.2013.10.054 · 2013 · External reference
Modified spatial architecture of regulatory T cells after neoadjuvant chemotherapy in non-small cell lung cancer patients
10.1016/j.intimp.2024.112434 · 2024 · External reference
Fc-Optimized Anti-CCR8 antibody depletes regulatory T cells in human tumor models
10.1158/0008-5472.can-20-3585 · 2021 · External reference
Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine
10.1038/s41467-020-17750-z · 2020 · External reference
Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance
10.1016/j.immuni.2007.08.014 · 2007 · External reference
Intracellular α-ketoglutarate maintains the pluripotency of embryonic stem cells
10.1038/nature13981 · 2015 · External reference
Combined PD-L1/TGFβ blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors
10.1038/s41467-023-40398-4 · 2023 · External reference
Metabolic competition in the tumor microenvironment is a driver of cancer progression
10.1016/j.cell.2015.08.016 · 2015 · External reference
mTOR coordinates transcriptional programs and mitochondrial metabolism of activated Treg subsets to protect tissue homeostasis
10.1038/s41467-018-04392-5 · 2018 · External reference
An essential role for the IL-2 receptor in Treg cell function
10.1038/ni.3540 · 2016 · External reference
PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells
10.1038/nature11132 · 2012 · External reference
Spatial multiplex analysis of lung cancer reveals that regulatory T cells attenuate KRAS-G12C inhibitor-induced immune responses
10.1126/sciadv.adl6464 · 2024 · External reference
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
10.1038/nm1093 · 2004 · External reference
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
10.1073/pnas.0915174107 · 2010 · External reference
Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1
10.1016/j.cell.2011.07.033 · 2011 · External reference
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells
10.1172/jci25947 · 2005 · External reference
Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells
10.1016/j.immuni.2016.10.021 · 2016 · External reference
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression
10.1084/jem.20062512 · 2007 · External reference
The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment
10.1016/j.immuni.2009.04.014 · 2009 · External reference
Beta-catenin stabilization extends regulatory T cell survival and induces anergy in nonregulatory T cells
10.1038/nm1707 · 2008 · External reference
CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients
10.4049/jimmunol.1402711 · 2015 · External reference
A phase I study of the Anti-CC chemokine receptor 4 antibody, mogamulizumab, in combination with nivolumab in patients with advanced or metastatic solid tumors
10.1158/1078-0432.ccr-19-1090 · 2019 · External reference
The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells
10.1158/0008-5472.can-07-5664 · 2008 · External reference
A temporal model of tumor-immune dynamics during the metastatic progression of high-grade serous ovarian cancer
10.1038/s41698-025-00973-y · 2025 · External reference
Spatial profiling technologies illuminate the tumor microenvironment
10.1016/j.ccell.2023.01.010 · 2023 · External reference
Spatial architecture of myeloid and T cells orchestrates immune evasion and clinical outcome in lung cancer
10.1158/2159-8290.cd-23-1380 · 2024 · External reference
A framework for multiplex imaging optimization and reproducible analysis
10.1038/s42003-022-03368-y · 2022 · External reference
Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy
10.1038/s41590-021-00958-6 · 2021 · External reference
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells
10.1038/nature10169 · 2011 · External reference
Type 1 Treg cells promote the generation of CD8+ tissue-resident memory T cells
10.1038/s41590-020-0674-9 · 2020 · External reference
Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters
10.1038/nm.2002 · 2009 · External reference
Epigenetic control of the foxp3 locus in regulatory T cells
10.1371/journal.pbio.0050038 · 2007 · External reference
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
10.1038/ni904 · 2003 · External reference
The dual role of treg in cancer
10.1111/sji.12615 · 2017 · External reference
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
10.1126/science.1129139 · 2006 · External reference
Safety and antitumor activity of a novel aCD25 Treg depleter RG6292 as a single agent and in combination with atezolizumab in patients with solid tumors
10.1158/2767-9764.crc-24-0638 · 2025 · External reference
Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development
10.1073/pnas.0509484103 · 2006 · External reference
Distinct immune cell populations define response to Anti-PD-1 monotherapy and Anti-PD-1/Anti-CTLA-4 combined therapy
10.1016/j.ccell.2019.01.003 · 2019 · External reference
Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry
10.1038/nmeth.2869 · 2014 · External reference
CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy
10.1038/s41467-021-23331-5 · 2021 · External reference
Conserved transcriptional connectivity of regulatory T cells in the tumor microenvironment informs new combination cancer therapy strategies
10.1038/s41590-023-01504-2 · 2023 · External reference
Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome
10.1158/0008-5472.can-08-2360 · 2009 · External reference
Deep profiling of mouse splenic architecture with CODEX multiplexed imaging
10.1016/j.cell.2018.07.010 · 2018 · External reference
Efficacy and safety of LM-108, an anti-CCR8 monoclonal antibody, in combination with an anti-PD-1 antibody in patients with gastric cancer: results from phase 1/2 studies
10.1200/jco.2024.42.16_suppl.2504 · 2024 · External reference
Spatial positioning and matrix programs of cancer-associated fibroblasts promote T-cell exclusion in human lung tumors
10.1158/2159-8290.cd-21-1714 · 2022 · External reference
Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing
10.1038/s41591-018-0045-3 · 2018 · External reference
Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma
10.1038/s43018-021-00221-9 · 2021 · External reference
Spatiotemporal analyses of the pan-cancer single-cell landscape reveal widespread profibrotic ecotypes associated with tumor immunity
10.1038/s43018-025-01039-5 · 2025 · External reference
Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses
10.1016/j.cell.2015.08.012 · 2015 · External reference
Improved survival with ipilimumab in patients with metastatic melanoma
10.1056/nejmoa1003466 · 2010 · External reference
Control of regulatory T cell development by the transcription factor Foxp3
10.1126/science.1079490 · 2003 · External reference
Tertiary lymphoid structure-associated B cells enhance CXCL13+CD103+CD8+ tissue-resident memory T-Cell response to programmed cell death protein 1 blockade in cancer immunotherapy
10.1053/j.gastro.2023.10.022 · 2024 · External reference
Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy
10.1038/s41423-021-00742-4 · 2022 · External reference
Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
10.1038/35001622 · 2000 · External reference
The single-cell pathology landscape of breast cancer
10.1038/s41586-019-1876-x · 2020 · External reference
Ex Vivo profiling of PD-1 blockade using organotypic tumor spheroids
10.1158/2159-8290.cd-17-0833 · 2018 · External reference
A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade
10.1016/j.cell.2018.09.006 · 2018 · External reference
Regulatory T cells: mechanisms of differentiation and function
10.1146/annurev.immunol.25.022106.141623 · 2012 · External reference
PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
10.1073/pnas.1822001116 · 2019 · External reference
Foxp3 expression in human cancer cells
10.1186/1479-5876-6-19 · 2008 · External reference
FDA approval summary: mogamulizumab-kpkc for mycosis fungoides and sézary syndrome
10.1158/1078-0432.ccr-19-2030 · 2019 · External reference
A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging
10.1016/j.cell.2018.08.039 · 2018 · External reference
An essential role for scurfin in CD4+CD25+ T regulatory cells
10.1038/ni909 · 2003 · External reference
CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory
10.1073/pnas.2114282119 · 2022 · External reference
Expression of Foxp3 in colorectal cancer but not in Treg cells correlates with disease progression in patients with colorectal cancer
10.1371/journal.pone.0053630 · 2013 · External reference
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
10.1016/s1470-2045(18)30379-6 · 2018 · External reference
Functional and dysfunctional T regulatory cell states in human tissues in RA and other autoimmune arthritic diseases
10.1038/s41590-026-02540-4 · 2026 · External reference
Constitutive expression of the transcriptional co-activator IκBζ promotes melanoma growth and immunotherapy resistance
10.1038/s41467-025-60929-5 · 2025 · External reference
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma
10.1084/jem.20050930 · 2006 · External reference
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments
10.1016/j.ccell.2022.01.001 · 2022 · External reference
Reprogramming cancer immunity with next-generation combination therapies
10.3389/fcell.2025.1652047 · 2025 · External reference
Regulatory T cells promote cancer immune-escape through integrin αvβ8-mediated TGF-β activation
10.1038/s41467-021-26352-2 · 2021 · External reference
Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses
10.1016/j.cell.2017.04.014 · 2017 · External reference
Benchmarking spatial and single-cell transcriptomics integration methods for transcript distribution prediction and cell type deconvolution
10.1038/s41592-022-01480-9 · External reference
TGF-β-dependent lymphoid tissue residency of stem-like T cells limits response to tumor vaccine
10.1038/s41467-022-33768-x · External reference
Structural basis of latent TGF-β1 presentation and activation by GARP on human regulatory T cells
10.1126/science.aau2909 · 2018 · External reference
Regulatory T cell-derived TGF-β signaling governs the differentiation and maintenance of tumor-infiltrating bystander CD8+ T cells
10.1016/j.celrep.2026.117189 · 2026 · External reference
Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial
10.1038/s41591-025-04032-8 · 2025 · External reference
Targeting regulatory T cells by E7777 enhances CD8 T-cell-mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models
10.3389/fimmu.2023.1268979 · 2023 · External reference
A conserved dendritic-cell regulatory program limits antitumour immunity
10.1038/s41586-020-2134-y · 2020 · External reference
Extricating human tumour immune alterations from tissue inflammation
10.1038/s41586-022-04718-w · 2022 · External reference
Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells
10.1074/jbc.m109.047423 · 2010 · External reference
Migratory DCs activate TGF-β to precondition naïve CD8+ T cells for tissue-resident memory fate
10.1126/science.aav5728 · 2019 · External reference
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
10.1038/nature25501 · 2018 · External reference
Histone methylation dynamics and gene regulation occur through the sensing of one-carbon metabolism
10.1016/j.cmet.2015.08.024 · 2015 · External reference
An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells
10.4049/jimmunol.0903670 · 2010 · External reference
Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets
10.4049/jimmunol.1003613 · 2011 · External reference
Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade
10.1038/s41590-019-0312-6 · 2019 · External reference
Runx3 programs CD8+ T cell residency in non-lymphoid tissues and tumours
10.1038/nature24993 · 2017 · External reference
Single-cell transcriptomics of regulatory T cells reveals trajectories of tissue adaptation
10.1016/j.immuni.2019.01.001 · 2019 · External reference
CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer
10.1002/ijc.23392 · 2008 · External reference
Spatial insights into immunotherapy response in non-small cell lung cancer (NSCLC) by multiplexed tissue imaging
10.1186/s12967-024-05035-8 · 2024 · External reference
Treg programming and therapeutic reprogramming in cancer
10.1111/imm.13058 · 2019 · External reference
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
10.1038/nm.3541 · 2014 · External reference
Stereotactic radiotherapy increases functionally suppressive regulatory T cells in the tumor microenvironment
10.1158/2326-6066.cir-17-0040 · 2017 · External reference
Fcgamma receptors as regulators of immune responses
10.1038/nri2206 · 2008 · External reference
Regulatory T cells in tumor immunity
10.1002/ijc.25429 · 2010 · External reference
Induction of resident memory T cells enhances the efficacy of cancer vaccine
10.1038/ncomms15221 · 2017 · External reference
Cancer vaccination drives Nanog-dependent evolution of tumor cells toward an immune-resistant and stem-like phenotype
10.1158/0008-5472.can-11-3758 · 2012 · External reference
T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development
10.1016/j.immuni.2012.09.010 · 2012 · External reference
A2A adenosine receptor protects tumors from antitumor T cells
10.1073/pnas.0605251103 · 2006 · External reference
CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells
10.1038/ni1536 · 2007 · External reference
Tissue tregs
10.1146/annurev-immunol-032712-095948 · 2016 · External reference
FDA approval summary: tremelimumab in combination with durvalumab for the treatment of patients with unresectable hepatocellular carcinoma
10.1158/1078-0432.ccr-23-2124 · 2024 · External reference
Spatially organized multicellular immune hubs in human colorectal cancer
10.1016/j.cell.2021.08.003 · 2021 · External reference
Loss of PTEN promotes resistance to T cell-mediated immunotherapy
10.1158/2159-8290.cd-15-0283 · 2016 · External reference
PD-L1 signaling selectively regulates T cell lymphatic transendothelial migration
10.1038/s41467-022-29930-0 · 2022 · External reference
OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
10.1084/jem.20071341 · 2008 · External reference
Regulatory T cells exhibit distinct features in human breast cancer
10.1016/j.immuni.2016.10.032 · 2016 · External reference
Immune-related adverse events associated with immune checkpoint blockade
10.1056/nejmra1703481 · 2018 · External reference
Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer
10.1016/j.cell.2017.10.044 · 2017 · External reference
Single-cell spatial multiomics reveals tumor microenvironment vulnerabilities in cancer resistance to immunotherapy
10.1016/j.celrep.2024.114392 · 2024 · External reference
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4
10.1126/science.1202947 · 2011 · External reference
Regulatory T cells characterized by low Id3 expression are highly suppressive and accumulate during chronic infection
10.18632/oncotarget.22159 · 2017 · External reference
PD-1 blockade expands intratumoral memory T cells
10.1158/2326-6066.cir-15-0210 · 2016 · External reference
Critical role for CD103(+)/CD141(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma
10.1016/j.ccell.2016.06.003 · 2016 · External reference
TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer
10.1136/jitc-2022-004991 · 2022 · External reference
Defining T cell states associated with response to checkpoint immunotherapy in melanoma
10.1016/j.cell.2018.10.038 · 2018 · External reference
An antibody targeting ICOS increases intratumoral cytotoxic to regulatory T-cell ratio and induces tumor regression
10.1158/2326-6066.cir-20-0034 · 2020 · External reference
Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers
10.1038/nm.4086 · 2016 · External reference
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases
10.1038/ni.1840 · 1995 · External reference
Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance
10.1034/j.1600-065x.2001.1820102.x · 2001 · External reference
Regulatory T cells and immune tolerance
10.1016/j.cell.2008.05.009 · 2008 · External reference
Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer
10.1200/jco.2008.18.7229 · 2009 · External reference
Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition
10.1016/j.immuni.2016.03.012 · 2016 · External reference
Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis
10.1038/s41591-018-0078-7 · 2018 · External reference
MCMICRO: a scalable, modular image-processing pipeline for multiplexed tissue imaging
10.1038/s41592-021-01308-y · External reference
MITI minimum information guidelines for highly multiplexed tissue images
10.1038/s41592-022-01415-4 · External reference
Scaling up spatial transcriptomics for large-sized tissues: uncovering cellular-level tissue architecture beyond conventional platforms with iSCALE
10.1038/s41592-025-02770-8 · 2025 · External reference
Coordinated cellular neighborhoods orchestrate antitumoral immunity at the colorectal cancer invasive front
10.1016/j.cell.2020.07.005 · 2020 · External reference
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells
10.1158/2326-6066.cir-13-0013 · 2013 · External reference
Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization
10.1084/jem.20041982 · 2005 · External reference
Oncogenic BRAFV600E governs regulatory T-cell recruitment during melanoma tumorigenesis
10.1158/0008-5472.can-18-0365 · 2018 · External reference
Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis
10.1038/srep15179 · 2015 · External reference
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase
10.1172/jci31911 · 2007 · External reference
Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers
10.1158/1078-0432.ccr-18-0762 · 2019 · External reference
WNT16B from ovarian fibroblasts induces differentiation of regulatory T cells through β-catenin signal in dendritic cells
10.3390/ijms150712928 · 2014 · External reference
Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity
10.4049/jimmunol.163.10.5211 · 1999 · External reference
Primary resistance to PD-1 blockade mediated by JAK1/2 mutations
10.1158/2159-8290.cd-16-1223 · 2017 · External reference
Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy
10.1016/j.immuni.2018.12.021 · 2019 · External reference
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
10.1084/jem.20130579 · 2013 · External reference
CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity
10.1038/s43018-020-00133-0 · 2020 · External reference
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
10.1038/nature14404 · 2015 · External reference
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans
10.1073/pnas.1316796110 · 2013 · External reference
Activated β-catenin in Foxp3+ regulatory T cells links inflammatory environments to autoimmunity
10.1038/s41590-018-0236-6 · 2018 · External reference
Targeting Treg cells in cancer immunotherapy
10.1002/eji.201847659 · 2019 · External reference
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
10.1038/nature25492 · 2018 · External reference
Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma
10.1056/nejmoa2109970 · 2022 · External reference
The immune landscape of cancer
10.1016/j.immuni.2018.03.023 · 2018 · External reference
Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer
10.1038/ni1549 · 2008 · External reference
Lung cancer-intrinsic SOX2 expression mediates resistance to checkpoint blockade therapy by inducing treg-dependent CD8+ T-cell exclusion
10.1158/2326-6066.cir-24-0184 · 2025 · External reference
GARP (LRRC32) is essential for the surface expression of latent TGF-beta on platelets and activated FOXP3+ regulatory T cells
10.1073/pnas.0901944106 · 2009 · External reference
Safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy from a first-in-human study of volrustomig, a novel PD-1/CTLA-4 bispecific antibody
10.1158/1078-0432.ccr-25-3447 · 2026 · External reference
The role of transcription factors in shaping regulatory T cell identity
10.1038/s41577-023-00893-7 · 2023 · External reference
PD-1 blockade induces responses by inhibiting adaptive immune resistance
10.1038/nature13954 · 2014 · External reference
Therapeutic depletion of CCR8+ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy
10.1136/jitc-2020-001749 · 2021 · External reference
Rapid temporal control of Foxp3 protein degradation by sirtuin-1
10.1371/journal.pone.0019047 · 2011 · External reference
Deletion of GARP on mouse regulatory T cells is not sufficient to inhibit the growth of transplanted tumors
10.1016/j.cellimm.2018.07.011 · 2018 · External reference
How regulatory T cells work
10.1038/nri2343 · 2008 · External reference
Cancer-FOXP3 directly activated CCL5 to recruit FOXP3+Treg cells in pancreatic ductal adenocarcinoma
10.1038/onc.2016.458 · 2017 · External reference
CHS-114: an afucosylated Anti-CCR8 monoclonal antibody that selectively depletes intratumoral treg cells and induces antitumor immune responses
10.1158/1535-7163.mct-25-0367 · 2026 · External reference
Metabolic support of tumour-infiltrating regulatory T cells by lactic acid
10.1038/s41586-020-03045-2 · 2021 · External reference
Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer
10.1158/1078-0432.ccr-13-1877 · 2014 · External reference
Mitochondrial complex III is essential for suppressive function of regulatory T cells
10.1038/s41586-018-0846-z · 2019 · External reference
ATP-citrate lyase links cellular metabolism to histone acetylation
10.1126/science.1164097 · 2009 · External reference
CCR8 marks highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function
10.1111/imm.13337 · 2021 · External reference
CTLA-4 control over Foxp3+ regulatory T cell function
10.1126/science.1160062 · 2008 · External reference
Integrin αvβ8-Mediated TGF-β activation by effector regulatory T cells is essential for suppression of T-Cell-Mediated inflammation
10.1016/j.immuni.2015.04.012 · 2015 · External reference
Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors
10.1038/s41467-023-40850-5 · 2023 · External reference
Systematic comparison of sequencing-based spatial transcriptomic methods
10.1038/s41592-024-02325-3 · 2024 · External reference
Control of Foxp3 stability through modulation of TET activity
10.1084/jem.20151438 · 2016 · External reference
Mogamulizumab in combination with durvalumab or tremelimumab in patients with advanced solid tumors: a phase I study
10.1158/1078-0432.ccr-20-0328 · 2020 · External reference
Mutations associated with acquired resistance to PD-1 blockade in melanoma
10.1056/nejmoa1604958 · 2016 · External reference
mTORC1 couples immune signals and metabolic programming to establish t(reg)-cell function
10.1038/nature12297 · 2013 · External reference
Analysis of CD8+ Treg cells in patients with ovarian cancer: a possible mechanism for immune impairment
10.1038/cmi.2015.57 · 2015 · External reference
Lineage tracking reveals dynamic relationships of T cells in colorectal cancer
10.1038/s41586-018-0694-x · 2018 · External reference
Regulatory T-cell depletion alters the tumor microenvironment and accelerates pancreatic carcinogenesis
10.1158/2159-8290.cd-19-0958 · 2020 · External reference
Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing
10.1016/j.cell.2017.05.035 · 2017 · External reference
